Literature DB >> 27474361

Loperamide-Related Deaths in North Carolina.

Sandra C Bishop-Freeman1, Marc S Feaster2, Jennifer Beal2, Alison Miller2, Robert L Hargrove2, Justin O Brower2, Ruth E Winecker2.   

Abstract

Loperamide (Imodium®) has been accepted as a safe, effective, over-the-counter anti-diarrheal drug with low potential for abuse. It is a synthetic opioid that lacks central nervous system activity at prescribed doses, rendering it ineffective for abuse. Since 2012, however, the North Carolina Office of the Chief Medical Examiner has seen cases involving loperamide at supratherapeutic levels that indicate abuse. The recommended dose associated with loperamide should not exceed 16 mg per day, although users seeking an opioid-like high reportedly take it in excess of 100 mg per dose. When taken as directed, the laboratory organic base extraction screening method with gas chromatography-mass spectrometry/nitrogen phosphorus detector lacks the sensitivity to detect loperamide. When taken in excess, the screening method identifies loperamide followed by a separate technique to confirm and quantify the drug by liquid chromatography-tandem mass spectrometry. Of the 21 cases involving loperamide, the pathologist implicated the drug as either additive or primary to the cause of death in 19 cases. The mean and median peripheral blood concentrations for the drug overdose cases were 0.27 and 0.23 mg/L, respectively. Furthermore, an extensive review of the pharmacology associated with loperamide and its interaction with P-glycoprotein will be examined as it relates to the mechanism of toxicity.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27474361     DOI: 10.1093/jat/bkw069

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  7 in total

Review 1.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

2.  Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects.

Authors:  Md Tariqul Haque Tuhin; Dengpan Liang; Fang Liu; Hala Aldawod; Toufiq Ul Amin; Joshua S Ho; Rasha Emara; Arjun D Patel; Melanie A Felmlee; Miki S Park; James A Uchizono; Mamoun M Alhamadsheh
Journal:  Nat Commun       Date:  2022-06-23       Impact factor: 17.694

3.  A commentary on operamide and cardiotoxicity.

Authors:  Salil R Rajayer; Charanya Sivaramakrishnan
Journal:  J Community Hosp Intern Med Perspect       Date:  2017-09-19

Review 4.  Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health.

Authors:  Barbara Lovrecic; Mercedes Lovrecic; Branko Gabrovec; Marco Carli; Matteo Pacini; Angelo G I Maremmani; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2019-01-09       Impact factor: 3.390

Review 5.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Brain Sci       Date:  2018-04-22

6.  Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.

Authors:  Fabrizio Schifano; Stefania Chiappini
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

7.  Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk.

Authors:  Mark R Davies; Michael Martinec; Robert Walls; Roman Schwarz; Gary R Mirams; Ken Wang; Guido Steiner; Andy Surinach; Carlos Flores; Thierry Lavé; Thomas Singer; Liudmila Polonchuk
Journal:  Cell Rep Med       Date:  2020-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.